Drug Description in Trials / DrugBank / KEGG DRUG


Search results


No. 薬物名(臨床試験情報から抽出) DrugBank KEGG DRUG KEGG GENES KEGG PATHWAY 指定難病告示番号
12-(4-[5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy)-N-(methylsulfonyl)actamide----1件: 86 💬
290 mg hydrocortisone acetate suppository with Sephure suppository applicator
(Acticort (TN))
3件: Acetate,
Hydrocortisone,
Hydrocortisone acetate (Actinac Pws)
2件: Hydrocortisone (Acticort (TN)),
Hydrocortisone acetate 💬
1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 97 💬
3A novel synthetic, orally-administered, non-peptide small molecule, which acts as----1件: 254 💬
4A novel synthetic, orally-administered, non-peptide small molecule, which acts as an agonist of the melanocortin-1 receptor (MC1R)----1件: 51 💬
5Abatacept Active Treatment1件: Abatacept1件: Abatacept 💬2件: CD80,
CD86 💬
13件: Allograft rejection, Autoimmune thyroid disease, Cell adhesion molecules, Graft-versus-host disease, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Rheumatoid arthritis, Systemic lupus erythematosus, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis, Virion - Adenovirus 💬1件: 50 💬
6Abatacept, rituximab or tocilizumab
(Actemra (TN))
3件: Abatacept,
Rituximab,
Tocilizumab (Actemra ACTPen)
3件: Tocilizumab (Actemra (TN)),
Rituximab ,
Abatacept 💬
4件: CD80,
CD86,
IL6R,
MS4A1 💬
25件: Allograft rejection, Autoimmune thyroid disease, Cell adhesion molecules, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, Graft-versus-host disease, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Rheumatoid arthritis, Systemic lupus erythematosus, Th17 cell differentiation, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis, Viral protein interaction with cytokine and cytokine receptor, Virion - Adenovirus 💬1件: 46 💬
7ACT----1件: 13 💬
8ACT - 064992----1件: 86 💬
9ACT-050089----1件: 86 💬
10ACT-050089 (Ro 61-0612)----1件: 86 💬
11ACT-064992----5件: 51, 85, 86, 88, 210 💬
12ACT-064992 (macitentan)1件: Macitentan1件: Macitentan 💬2件: EDNRA,
EDNRB 💬
9件: Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬1件: 85 💬
13ACT-064992 / JNJ-67896062----1件: 86 💬
14ACT-064992/ JNJ-67896062----1件: 86 💬
15ACT-064992D----1件: 86 💬
16ACT-1----1件: 13 💬
17ACT-128800----1件: 13 💬
18ACT-128800 Dose 1----1件: 13 💬
19ACT-128800 Dose 2----1件: 13 💬
20ACT-128800 Dose 3----1件: 13 💬
21ACT-178418----1件: 86 💬
22ACT-293987----3件: 51, 86, 88 💬
23ACT-293987 (NS-304)----1件: 86 💬
24ACT-293987 / JNJ-67896049----1件: 84 💬
25ACT-334441----1件: 49 💬
26ACT-385781A----1件: 86 💬
27ACT-385781A (Actelion Epoprostenol)1件: Epoprostenol1件: Epoprostenol 💬1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86 💬
28ACT-434964----1件: 19 💬
29Act-HiB1件: Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen (ActHIB)---4件: 14, 61, 62, 222 💬
30ACT-HIB Polvere e solvente per soluzione iniettabile in siringa preriempita 0,5 ml1件: Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen (ActHIB)---2件: 61, 62 💬
31Actemra1件: Tocilizumab (Actemra ACTPen)1件: Tocilizumab (Actemra (TN)) 💬1件: IL6R 💬12件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬2件: 46, 107 💬
32Actemra(EU-licensed)1件: Tocilizumab (Actemra ACTPen)1件: Tocilizumab (Actemra (TN)) 💬1件: IL6R 💬12件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬1件: 46 💬
33Actemra, MRA1件: Tocilizumab (Actemra ACTPen)1件: Tocilizumab (Actemra (TN)) 💬1件: IL6R 💬12件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬1件: 107 💬
34Acteoside1件: Acteoside---1件: 66 💬
35ACTH1件: Corticotropin (Acthar)1件: Corticotropin (ACTH (TN)) 💬1件: MC2R 💬5件: Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬4件: 13, 66, 145, 222 💬
36ACTH (Acthar) Gel1件: Corticotropin (Acthar)1件: Corticotropin (ACTH (TN)) 💬1件: MC2R 💬5件: Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬1件: 66 💬
37Acthar1件: Corticotropin (Acthar)1件: Corticotropin (ACTH (TN)) 💬1件: MC2R 💬5件: Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬9件: 2, 13, 14, 46, 49, 50, 66, 84, 222 💬
38Acthar 80 unit injection1件: Corticotropin (Acthar)1件: Corticotropin (ACTH (TN)) 💬1件: MC2R 💬5件: Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬1件: 66 💬
39Acthar Gel1件: Corticotropin (Acthar)1件: Corticotropin (ACTH (TN)) 💬1件: MC2R 💬5件: Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬6件: 13, 46, 49, 50, 84, 222 💬
40ACTHAR Gel (ACTH)1件: Corticotropin (Acthar)1件: Corticotropin (ACTH (TN)) 💬1件: MC2R 💬5件: Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬1件: 13 💬
41ACTHAR Gel (adrenocorticotropic hormone)1件: Corticotropin (Acthar)1件: Corticotropin (ACTH (TN)) 💬1件: MC2R 💬5件: Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬1件: 84 💬
42ACTHAR Gel 40 units twice weekly1件: Corticotropin (Acthar)1件: Corticotropin (ACTH (TN)) 💬1件: MC2R 💬5件: Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬1件: 84 💬
43ACTHAR Gel 80 units twice weekly.1件: Corticotropin (Acthar)1件: Corticotropin (ACTH (TN)) 💬1件: MC2R 💬5件: Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬1件: 84 💬
44Acthar high dose (80 U)1件: Corticotropin (Acthar)1件: Corticotropin (ACTH (TN)) 💬1件: MC2R 💬5件: Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬1件: 49 💬
45Acthar Injectable Product1件: Corticotropin (Acthar)1件: Corticotropin (ACTH (TN)) 💬1件: MC2R 💬5件: Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬1件: 46 💬
46Acthar low dose (40 U)1件: Corticotropin (Acthar)1件: Corticotropin (ACTH (TN)) 💬1件: MC2R 💬5件: Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬1件: 49 💬
47ActHIB1件: Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen (ActHIB)---2件: 62, 66 💬
48ACTHIB - POLVERE E SOLVENTE PER SOLUZIONE INIETTABILE 1 FLACONCINO POLVERE+1 SIRINGA PRERIEMPITA SOLVENTE 0.5 ML1件: Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen (ActHIB)---2件: 62, 66 💬
49Acthrel1件: Corticorelin ovine triflutate (Acthrel)1件: Corticorelin ovine triflutate (Acthrel (TN)) 💬2件: CRHR1,
CRHR2 💬
4件: Cushing syndrome, Long-term depression, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬1件: 75 💬
50ACTIMMUNE1件: Interferon gamma-1b (Actimmune)1件: Interferon gamma-1b (Actimmune (TN)) 💬2件: IFNGR1,
IFNGR2 💬
18件: Chagas disease, Cytokine-cytokine receptor interaction, HIF-1 signaling pathway, Herpes simplex virus 1 infection, Inflammatory bowel disease, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways in cancer, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis 💬1件: 326 💬
51Actimmune Registry1件: Interferon gamma-1b (Actimmune)1件: Interferon gamma-1b (Actimmune (TN)) 💬2件: IFNGR1,
IFNGR2 💬
18件: Chagas disease, Cytokine-cytokine receptor interaction, HIF-1 signaling pathway, Herpes simplex virus 1 infection, Inflammatory bowel disease, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways in cancer, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis 💬1件: 326 💬
52Active BMN 111: Subcutaneous injection of recommended dose of BMN 111 based on weight-band dosing once daily.----1件: 276 💬
53Active comparator----2件: 6, 46 💬
54Active Comparator receiving Extavia®1件: Interferon beta-1b1件: Interferon beta-1b 💬2件: IFNAR1,
IFNAR2 💬
18件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬1件: 13 💬
55Active Control----1件: 13 💬
56Active drug (BIIB014) at 10, 30, 100, or 300 mg once daily.----1件: 6 💬
57Active drug: pimavanserin 17mg (2 strength tablets)1件: Pimavanserin---1件: 6 💬
58Active Investigational Treatment ENT-01----1件: 6 💬
59Active topical NS2 1% dermatologic cream----1件: 160 💬
60Active Treatment Group 7% Hypertonic Saline----1件: 299 💬
61ActiveMatrix----1件: 70 💬
62Actonel 5mg Film Coated Tablets1件: Risedronic acid (Actonel Plus Calcium)1件: Risedronic acid 💬1件: FDPS 💬4件: Human T-cell leukemia virus 1 infection, Influenza A, Metabolic pathways, Terpenoid backbone biosynthesis 💬1件: 274 💬
63Actonel Once a Week 35 mg film-coated tablets1件: Risedronic acid (Actonel Plus Calcium)1件: Risedronic acid 💬1件: FDPS 💬4件: Human T-cell leukemia virus 1 infection, Influenza A, Metabolic pathways, Terpenoid backbone biosynthesis 💬1件: 274 💬
64Actonel Once a week 5mg film coated tablets1件: Risedronic acid (Actonel Plus Calcium)1件: Risedronic acid 💬1件: FDPS 💬4件: Human T-cell leukemia virus 1 infection, Influenza A, Metabolic pathways, Terpenoid backbone biosynthesis 💬1件: 113 💬
65Actonel/Optinate 5mg film-coated tablets1件: Risedronic acid (Actonel Plus Calcium)1件: Risedronic acid 💬1件: FDPS 💬4件: Human T-cell leukemia virus 1 infection, Influenza A, Metabolic pathways, Terpenoid backbone biosynthesis 💬1件: 274 💬
66ACTOS (Pioglitazone)1件: Pioglitazone (Actoplus Met)1件: Pioglitazone (Actos (TN)) 💬1件: PPARG 💬11件: AMPK signaling pathway, Huntington disease, Lipid and atherosclerosis, Longevity regulating pathway, Non-alcoholic fatty liver disease, Osteoclast differentiation, PPAR signaling pathway, Pathways in cancer, Thermogenesis, Thyroid cancer, Transcriptional misregulation in cancer 💬1件: 13 💬
67Actos 15 mg1件: Pioglitazone (Actoplus Met)1件: Pioglitazone (Actos (TN)) 💬1件: PPARG 💬11件: AMPK signaling pathway, Huntington disease, Lipid and atherosclerosis, Longevity regulating pathway, Non-alcoholic fatty liver disease, Osteoclast differentiation, PPAR signaling pathway, Pathways in cancer, Thermogenesis, Thyroid cancer, Transcriptional misregulation in cancer 💬1件: 2 💬
68Actos 30 mg1件: Pioglitazone (Actoplus Met)1件: Pioglitazone (Actos (TN)) 💬1件: PPARG 💬11件: AMPK signaling pathway, Huntington disease, Lipid and atherosclerosis, Longevity regulating pathway, Non-alcoholic fatty liver disease, Osteoclast differentiation, PPAR signaling pathway, Pathways in cancer, Thermogenesis, Thyroid cancer, Transcriptional misregulation in cancer 💬1件: 2 💬
69Actos 45 mg1件: Pioglitazone (Actoplus Met)1件: Pioglitazone (Actos (TN)) 💬1件: PPARG 💬11件: AMPK signaling pathway, Huntington disease, Lipid and atherosclerosis, Longevity regulating pathway, Non-alcoholic fatty liver disease, Osteoclast differentiation, PPAR signaling pathway, Pathways in cancer, Thermogenesis, Thyroid cancer, Transcriptional misregulation in cancer 💬1件: 2 💬
70Actrapid 100 IU/ml, Solution for injection in a vial----1件: 299 💬
71Actrapid Penfill 100UI/ml----1件: 299 💬
72ActRIIA-IgG1Fc----1件: 86 💬
73ACTUS-101----1件: 256 💬
74Adalimuab, Etanercept, Tocilizumab, or Abatacept
(Actemra (TN))
3件: Abatacept,
Etanercept,
Tocilizumab (Actemra ACTPen)
3件: Etanercept ,
Tocilizumab (Actemra (TN)),
Abatacept 💬
5件: CD80,
CD86,
IL6R,
LTA,
TNF 💬
80件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, Autoimmune thyroid disease, C-type lectin receptor signaling pathway, Cell adhesion molecules, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, HIF-1 signaling pathway, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Transcriptional misregulation in cancer, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral myocarditis, Viral protein interaction with cytokine and cytokine receptor, Virion - Adenovirus, Yersinia infection, mTOR signaling pathway 💬1件: 46 💬
75Adjuvant without active component----2件: 6, 17 💬
76Adrenocorticotrophic hormone ACTH1件: Corticotropin (Acthar)1件: Corticotropin (ACTH (TN)) 💬1件: MC2R 💬5件: Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬1件: 222 💬
77Adrenocorticotropic hormone (ACTH) gel (H.P. Acthar®)1件: Corticotropin (Acthar)1件: Corticotropin (ACTH (TN)) 💬1件: MC2R 💬5件: Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬1件: 13 💬
78Anti BAFF (B cell activating factor)----1件: 49 💬
79Anxiety/depression and work and activities----1件: 13 💬
80Biologically active human fecal microbiota----1件: 97 💬
81BT-11 Active----2件: 96, 97 💬
82CFZ533 active - Cohort 1----1件: 53 💬
83CFZ533 active - Cohort 2----1件: 53 💬
84CFZ533 active - Cohort 3----1件: 53 💬
85CFZ533 active -Cohort 3----1件: 53 💬
86CJNJ-68150420-ZZZ-G001 (ACT- 064992D)----1件: 86 💬
87CJNJ-68150420-ZZZ-G001 (ACT-064992D)----1件: 86 💬
88CJNJ-68150420-ZZZ-G001(ACT-064992D)----1件: 86 💬
89Combination Oral Budesonide and Rectal Hydrocortisone
(Acticort (TN))
2件: Budesonide,
Hydrocortisone
2件: Hydrocortisone (Acticort (TN)),
Budesonide 💬
1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 97 💬
90Combination Product: Active treatment with dual therapy----1件: 2 💬
91Conventional Glucocorticoids (immediate release hydrocortisone, cortisone acetate, prednisone, prednisolone, dexamethasone)
(Acticort (TN))
7件: Acetate,
Cortisone,
Cortisone acetate,
Dexamethasone,
Hydrocortisone,
Prednisolone,
Prednisone
6件: Hydrocortisone (Acticort (TN)),
Dexamethasone ,
Prednisolone ,
Prednisone ,
Cortisone acetate ,
Cortisone 💬
1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 81 💬
92Cortef (hydrocortisone)
(Acticort (TN))
1件: Hydrocortisone1件: Hydrocortisone (Acticort (TN)) 💬1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 83 💬
93Corticoids+ tocilizumab 8mg/Kg/4 weeks
(Actemra (TN))
1件: Tocilizumab (Actemra ACTPen)1件: Tocilizumab (Actemra (TN)) 💬1件: IL6R 💬12件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬1件: 41 💬
94Corticotropin
(ACTH (TN))
1件: Corticotropin (Acthar)1件: Corticotropin (ACTH (TN)) 💬1件: MC2R 💬5件: Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬7件: 2, 13, 46, 75, 81, 84, 222 💬
95Corticotropin-releasing hormone
(ACTH (TN))
2件: Corticorelin,
Corticotropin (Acthar)
2件: Corticotropin (ACTH (TN)),
Corticorelin 💬
3件: CRHR1,
CRHR2,
MC2R 💬
6件: Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Long-term depression, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬1件: 75 💬
96Crinecerfont is a novel non-peptide selective corticotropin releasing factor 1 (CRF1 ) receptor antagonist.
(ACTH (TN))
1件: Corticotropin (Acthar)1件: Corticotropin (ACTH (TN)) 💬1件: MC2R 💬5件: Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬1件: 81 💬
97CT-P47 AI (tocilizumab)
(Actemra (TN))
1件: Tocilizumab (Actemra ACTPen)1件: Tocilizumab (Actemra (TN)) 💬1件: IL6R 💬12件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬1件: 46 💬
98CT-P47 PFS (tocilizumab)
(Actemra (TN))
1件: Tocilizumab (Actemra ACTPen)1件: Tocilizumab (Actemra (TN)) 💬1件: IL6R 💬12件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬1件: 46 💬
99Decrease Tocilizumab, Abatacept
(Actemra (TN))
2件: Abatacept,
Tocilizumab (Actemra ACTPen)
2件: Tocilizumab (Actemra (TN)),
Abatacept 💬
3件: CD80,
CD86,
IL6R 💬
25件: Allograft rejection, Autoimmune thyroid disease, Cell adhesion molecules, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, Graft-versus-host disease, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Rheumatoid arthritis, Systemic lupus erythematosus, Th17 cell differentiation, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis, Viral protein interaction with cytokine and cytokine receptor, Virion - Adenovirus 💬1件: 46 💬
100Dual release hydrocortisone (plenadren)
(Acticort (TN))
1件: Hydrocortisone1件: Hydrocortisone (Acticort (TN)) 💬1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 81 💬
101EFI/ACT-385781A----1件: 86 💬
102Epoprostenol-Actelion1件: Epoprostenol1件: Epoprostenol 💬1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86 💬
103Etanercepet, Rituximab, Abatacept, Tocilizumab, Sarilumab
(Actemra (TN))
4件: Abatacept,
Rituximab,
Sarilumab,
Tocilizumab (Actemra ACTPen)
4件: Tocilizumab (Actemra (TN)),
Rituximab ,
Abatacept ,
Sarilumab 💬
4件: CD80,
CD86,
IL6R,
MS4A1 💬
25件: Allograft rejection, Autoimmune thyroid disease, Cell adhesion molecules, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, Graft-versus-host disease, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Rheumatoid arthritis, Systemic lupus erythematosus, Th17 cell differentiation, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis, Viral protein interaction with cytokine and cytokine receptor, Virion - Adenovirus 💬1件: 46 💬
104Fenofibrate Combined With Ursodeoxycholic Acid
(Actigall (TN))
2件: Fenofibrate,
Ursodeoxycholic acid (Actigall)
2件: Fenofibrate ,
Ursodiol (Actigall (TN)) 💬
2件: NR1H4,
PPARA 💬
11件: Adipocytokine signaling pathway, Alcoholic liver disease, Bile secretion, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬1件: 93 💬
105Gene Activated a-Galactosidase A----1件: 19 💬
106Gene Activated Human Glucocerebrosidase----1件: 19 💬
107Gene activated human glucocerebrosidase, velaglucerase alfa1件: Velaglucerase alfa1件: Velaglucerase alfa 💬1件: GBA1 💬4件: Lysosome, Metabolic pathways, Other glycan degradation, Sphingolipid metabolism 💬1件: 19 💬
108Gene-Activated Human Glucocerebrosidase----1件: 19 💬
109Gene-Activated Human Glucocerebrosidase 200U/vial----1件: 19 💬
110Gene-Activated Human Glucocerebrosidase 400U/vial----1件: 19 💬
111H.P. Acthar Gel1件: Corticotropin (Acthar)1件: Corticotropin (ACTH (TN)) 💬1件: MC2R 💬5件: Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬5件: 46, 49, 50, 84, 222 💬
112H.P. Acthar Gel (repository corticotropin injection)1件: Corticotropin (Acthar)1件: Corticotropin (ACTH (TN)) 💬1件: MC2R 💬5件: Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬1件: 13 💬
113H.P. Acthar® Gel1件: Corticotropin (Acthar)1件: Corticotropin (ACTH (TN)) 💬1件: MC2R 💬5件: Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬1件: 14 💬
114HrIL-2 active----3件: 46, 49, 53 💬
115Hydrocortisone
(Acticort (TN))
2件: Hydrocortisone,
Hydrocortisone acetate (Actinac Pws)
2件: Hydrocortisone (Acticort (TN)),
Hydrocortisone acetate 💬
1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬10件: 6, 41, 46, 53, 75, 78, 81, 83, 97, 299 💬
116Hydrocortisone (Solucortef)
(Acticort (TN))
1件: Hydrocortisone1件: Hydrocortisone (Acticort (TN)) 💬1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 81 💬
117Hydrocortisone 100mg/ml
(Acticort (TN))
1件: Hydrocortisone1件: Hydrocortisone (Acticort (TN)) 💬1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 83 💬
118Hydrocortisone 10mg
(Acticort (TN))
1件: Hydrocortisone1件: Hydrocortisone (Acticort (TN)) 💬1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 46 💬
119Hydrocortisone 10mg Tablet
(Acticort (TN))
1件: Hydrocortisone1件: Hydrocortisone (Acticort (TN)) 💬1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 81 💬
120Hydrocortisone 10mg Tablets
(Acticort (TN))
1件: Hydrocortisone1件: Hydrocortisone (Acticort (TN)) 💬1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 81 💬
121Hydrocortisone 20mg Tablets
(Acticort (TN))
1件: Hydrocortisone1件: Hydrocortisone (Acticort (TN)) 💬1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 81 💬
122HYDROCORTISONE ACETATE
(Acticort (TN))
3件: Acetate,
Hydrocortisone,
Hydrocortisone acetate (Actinac Pws)
2件: Hydrocortisone (Acticort (TN)),
Hydrocortisone acetate 💬
1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 97 💬
123Hydrocortisone cream
(Acticort (TN))
1件: Hydrocortisone1件: Hydrocortisone (Acticort (TN)) 💬1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 6 💬
124Hydrocortisone cream 1%
(Acticort (TN))
1件: Hydrocortisone1件: Hydrocortisone (Acticort (TN)) 💬1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 6 💬
125Hydrocortisone cream 10mg/g FNA Fagron
(Acticort (TN))
1件: Hydrocortisone1件: Hydrocortisone (Acticort (TN)) 💬1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 6 💬
126HYDROCORTISONE HYDROGEN SUCCINATE
(Acticort (TN))
3件: Hydrocortisone,
Hydrocortisone succinate,
Hydrogen
2件: Hydrocortisone (Acticort (TN)),
Hydrocortisone succinate 💬
1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 83 💬
127HYDROCORTISONE MICRONIZED
(Acticort (TN))
1件: Hydrocortisone1件: Hydrocortisone (Acticort (TN)) 💬1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 81 💬
128Hydrocortisone Modified Release Capsules
(Acticort (TN))
1件: Hydrocortisone1件: Hydrocortisone (Acticort (TN)) 💬1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 81 💬
129HYDROCORTISONE ROUSSEL
(Acticort (TN))
1件: Hydrocortisone1件: Hydrocortisone (Acticort (TN)) 💬1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 83 💬
130Hydrocortisone sodium acetate
(Acticort (TN))
3件: Acetate,
Hydrocortisone,
Sodium acetate
2件: Hydrocortisone (Acticort (TN)),
Sodium acetate 💬
1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 81 💬
131HYDROCORTISONE SODIUM PHOSPHATE
(Acticort (TN))
2件: Hydrocortisone,
Phosphate ion
1件: Hydrocortisone (Acticort (TN)) 💬1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬3件: 53, 81, 83 💬
132HYDROCORTISONE SODIUM SUCCINATE
(Acticort (TN))
1件: Hydrocortisone1件: Hydrocortisone (Acticort (TN)) 💬1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬3件: 81, 83, 97 💬
133Hydrocortisone tablet 2.5 mg
(Acticort (TN))
1件: Hydrocortisone1件: Hydrocortisone (Acticort (TN)) 💬1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 81 💬
134Hydrocortisone TAKEDA, tabletter
(Acticort (TN))
1件: Hydrocortisone1件: Hydrocortisone (Acticort (TN)) 💬1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 78 💬
135HYDROCORTISONE- hydrocortisone tablet
(Acticort (TN))
1件: Hydrocortisone1件: Hydrocortisone (Acticort (TN)) 💬1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 81 💬
136INN-Tocilizumab
(Actemra (TN))
1件: Tocilizumab (Actemra ACTPen)1件: Tocilizumab (Actemra (TN)) 💬1件: IL6R 💬12件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬1件: 266 💬
137INTERFERON GAMMA-1B
(Actimmune (TN))
2件: Interferon Gamma,
Interferon gamma-1b (Actimmune)
1件: Interferon gamma-1b (Actimmune (TN)) 💬2件: IFNGR1,
IFNGR2 💬
18件: Chagas disease, Cytokine-cytokine receptor interaction, HIF-1 signaling pathway, Herpes simplex virus 1 infection, Inflammatory bowel disease, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways in cancer, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis 💬7件: 18, 65, 85, 228, 299, 301, 326 💬
138Interferon gamma-1b (Actimmune)2件: Interferon Gamma,
Interferon gamma-1b (Actimmune)
1件: Interferon gamma-1b (Actimmune (TN)) 💬2件: IFNGR1,
IFNGR2 💬
18件: Chagas disease, Cytokine-cytokine receptor interaction, HIF-1 signaling pathway, Herpes simplex virus 1 infection, Inflammatory bowel disease, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways in cancer, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis 💬1件: 85 💬
139Intra-articular Tocilizumab
(Actemra (TN))
1件: Tocilizumab (Actemra ACTPen)1件: Tocilizumab (Actemra (TN)) 💬1件: IL6R 💬12件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬1件: 46 💬
140JNJ-67896049 (ACT-293987)----1件: 86 💬
141JNJ-67896062 / ACT-064992----2件: 86, 88 💬
142JNJ-67896062/ ACT-064992----2件: 86, 88 💬
143JNJ-67896062/ACT-064922----1件: 86 💬
144JNJ-67896153/ACT-128800----1件: 13 💬
145Lamotrigin actavis----1件: 114 💬
146Long-Acting Growth Hormone (LAGH)1件: Somatotropin---1件: 78 💬
147Long-acting somatostatin1件: Somatostatin1件: Somatostatin 💬5件: SSTR1,
SSTR2,
SSTR3,
SSTR4,
SSTR5 💬
4件: Gastric acid secretion, Growth hormone synthesis, secretion and action, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬1件: 67 💬
148Macitentan (ACT-064992)1件: Macitentan1件: Macitentan 💬2件: EDNRA,
EDNRB 💬
9件: Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬1件: 86 💬
149Mesalazine with hydrocortisone sodium succinate
(Acticort (TN))
2件: Hydrocortisone,
Mesalazine
2件: Hydrocortisone (Acticort (TN)),
Mesalamine 💬
1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 97 💬
150MRA (Actemra)1件: Tocilizumab (Actemra ACTPen)1件: Tocilizumab (Actemra (TN)) 💬1件: IL6R 💬12件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬1件: 107 💬
151MRA (tocilizumab)
(Actemra (TN))
1件: Tocilizumab (Actemra ACTPen)1件: Tocilizumab (Actemra (TN)) 💬1件: IL6R 💬12件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬2件: 46, 107 💬
152MRA(Tocilizumab)
(Actemra (TN))
1件: Tocilizumab (Actemra ACTPen)1件: Tocilizumab (Actemra (TN)) 💬1件: IL6R 💬12件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬2件: 46, 107 💬
153MRA, Actemra1件: Tocilizumab (Actemra ACTPen)1件: Tocilizumab (Actemra (TN)) 💬1件: IL6R 💬12件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬2件: 46, 107 💬
154Novorapid / humalog short acting insulin----1件: 299 💬
155Octreotide LAR / Sandostatin LAR (LAR=long acting release)1件: Octreotide1件: Octreotide 💬1件: SSTR2 💬4件: Gastric acid secretion, Growth hormone synthesis, secretion and action, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬1件: 84 💬
156Ovine Corticotropin-Releasing Hormone (oCRH)
(ACTH (TN))
2件: Corticorelin,
Corticotropin (Acthar)
2件: Corticotropin (ACTH (TN)),
Corticorelin 💬
3件: CRHR1,
CRHR2,
MC2R 💬
6件: Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Long-term depression, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬1件: 75 💬
157Pioglitazone
(Actos (TN))
1件: Pioglitazone (Actoplus Met)1件: Pioglitazone (Actos (TN)) 💬1件: PPARG 💬11件: AMPK signaling pathway, Huntington disease, Lipid and atherosclerosis, Longevity regulating pathway, Non-alcoholic fatty liver disease, Osteoclast differentiation, PPAR signaling pathway, Pathways in cancer, Thermogenesis, Thyroid cancer, Transcriptional misregulation in cancer 💬17件: 2, 6, 13, 15, 20, 46, 49, 65, 67, 78, 81, 86, 96, 229, 265, 298, 299 💬
158Pioglitazone 15 mg
(Actos (TN))
1件: Pioglitazone (Actoplus Met)1件: Pioglitazone (Actos (TN)) 💬1件: PPARG 💬11件: AMPK signaling pathway, Huntington disease, Lipid and atherosclerosis, Longevity regulating pathway, Non-alcoholic fatty liver disease, Osteoclast differentiation, PPAR signaling pathway, Pathways in cancer, Thermogenesis, Thyroid cancer, Transcriptional misregulation in cancer 💬1件: 96 💬
159Pioglitazone and Tretinoin
(Actos (TN))
2件: Pioglitazone (Actoplus Met),
Tretinoin
2件: Tretinoin ,
Pioglitazone (Actos (TN)) 💬
4件: PML,
PPARG,
RARA,
RARB 💬
21件: AMPK signaling pathway, Acute myeloid leukemia, Endocytosis, Estrogen signaling pathway, Gastric cancer, Herpes simplex virus 1 infection, Huntington disease, Influenza A, Lipid and atherosclerosis, Longevity regulating pathway, Non-alcoholic fatty liver disease, Non-small cell lung cancer, Osteoclast differentiation, PPAR signaling pathway, Pathways in cancer, Small cell lung cancer, Th17 cell differentiation, Thermogenesis, Thyroid cancer, Transcriptional misregulation in cancer, Ubiquitin mediated proteolysis 💬1件: 2 💬
160Pioglitazone or metformin
(Actos (TN))
2件: Metformin (Actoplus Met),
Pioglitazone (Actoplus Met)
2件: Metformin ,
Pioglitazone (Actos (TN)) 💬
3件: PPARG,
PRKAA1,
PRKAA2 💬
27件: AMPK signaling pathway, Adipocytokine signaling pathway, Alcoholic liver disease, Apelin signaling pathway, Autophagy - animal, Circadian rhythm, Fluid shear stress and atherosclerosis, FoxO signaling pathway, Glucagon signaling pathway, Huntington disease, Hypertrophic cardiomyopathy, Insulin resistance, Insulin signaling pathway, Lipid and atherosclerosis, Longevity regulating pathway, Longevity regulating pathway - multiple species, Non-alcoholic fatty liver disease, Osteoclast differentiation, Oxytocin signaling pathway, PI3K-Akt signaling pathway, PPAR signaling pathway, Pathways in cancer, Thermogenesis, Thyroid cancer, Tight junction, Transcriptional misregulation in cancer, mTOR signaling pathway 💬1件: 265 💬
161Reh-acteoside1件: Acteoside---1件: 66 💬
162Repository Corticotropin Injection
(ACTH (TN))
1件: Corticotropin (Acthar)1件: Corticotropin (ACTH (TN)) 💬1件: MC2R 💬5件: Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬5件: 2, 13, 46, 84, 222 💬
163Risedronate sodium (Actonel)1件: Risedronic acid (Actonel Plus Calcium)1件: Risedronic acid 💬1件: FDPS 💬4件: Human T-cell leukemia virus 1 infection, Influenza A, Metabolic pathways, Terpenoid backbone biosynthesis 💬1件: 274 💬
164Rituximab, observational study amon patients with active RA1件: Rituximab1件: Rituximab 💬1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 46 💬
165Ro 47-0203 / ACT-050088----1件: 86 💬
166Ro Actemra1件: Tocilizumab (Actemra ACTPen)1件: Tocilizumab (Actemra (TN)) 💬1件: IL6R 💬12件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬1件: 46 💬
167Ro-Actemra1件: Tocilizumab (Actemra ACTPen)1件: Tocilizumab (Actemra (TN)) 💬1件: IL6R 💬12件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬2件: 46, 107 💬
168Ro47-0203 / ACT-050088----2件: 51, 86 💬
169RoActemra/Actemra (tocilizumab)1件: Tocilizumab (Actemra ACTPen)1件: Tocilizumab (Actemra (TN)) 💬1件: IL6R 💬12件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬1件: 107 💬
170Selexipag, ACT-293987 (NS-304)1件: Selexipag1件: Selexipag 💬1件: PTGIR 💬3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬1件: 86 💬
171Short-acting Insulin (Actrapid)----1件: 299 💬
172Solu-Cortef (hydrocortisone)
(Acticort (TN))
1件: Hydrocortisone1件: Hydrocortisone (Acticort (TN)) 💬1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 83 💬
173Solu-Cortef, powder for solution for injection, 100mg, and 'Act-O-Vial'3件: Hydrocortisone,
Hydrocortisone cypionate,
Hydrocortisone succinate
3件: Hydrocortisone (Acticort (TN)),
Hydrocortisone cypionate ,
Hydrocortisone succinate 💬
1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 6 💬
174Subcutaneous hydrocortisone 10mg
(Acticort (TN))
1件: Hydrocortisone1件: Hydrocortisone (Acticort (TN)) 💬1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 6 💬
175Subcutaneous tocilizumab
(Actemra (TN))
1件: Tocilizumab (Actemra ACTPen)1件: Tocilizumab (Actemra (TN)) 💬1件: IL6R 💬12件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬1件: 46 💬
176Subcutaneous tocilizumab 162mg/biweekly
(Actemra (TN))
1件: Tocilizumab (Actemra ACTPen)1件: Tocilizumab (Actemra (TN)) 💬1件: IL6R 💬12件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬1件: 46 💬
177Time and attention + active fructooligosaccharide supplementation----1件: 96 💬
178TOCILIZUMAB
(Actemra (TN))
1件: Tocilizumab (Actemra ACTPen)1件: Tocilizumab (Actemra (TN)) 💬1件: IL6R 💬12件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬21件: 2, 11, 13, 40, 41, 42, 43, 44, 46, 49, 50, 51, 53, 54, 55, 56, 86, 107, 266, 271, 331 💬
179Tocilizumab (Actemra or RoActemra)1件: Tocilizumab (Actemra ACTPen)1件: Tocilizumab (Actemra (TN)) 💬1件: IL6R 💬12件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬1件: 46 💬
180Tocilizumab (Actemra)1件: Tocilizumab (Actemra ACTPen)1件: Tocilizumab (Actemra (TN)) 💬1件: IL6R 💬12件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬1件: 46 💬
181Tocilizumab (Actemra®)1件: Tocilizumab (Actemra ACTPen)1件: Tocilizumab (Actemra (TN)) 💬1件: IL6R 💬12件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬1件: 46 💬
182Tocilizumab (MRA-SC)
(Actemra (TN))
1件: Tocilizumab (Actemra ACTPen)1件: Tocilizumab (Actemra (TN)) 💬1件: IL6R 💬12件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬1件: 40 💬
183Tocilizumab (TCZ)
(Actemra (TN))
1件: Tocilizumab (Actemra ACTPen)1件: Tocilizumab (Actemra (TN)) 💬1件: IL6R 💬12件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬2件: 46, 56 💬
184Tocilizumab + Glucocorticoids (GCs)
(Actemra (TN))
1件: Tocilizumab (Actemra ACTPen)1件: Tocilizumab (Actemra (TN)) 💬1件: IL6R 💬12件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬1件: 41 💬
185Tocilizumab + methotrexate(MTX)
(Actemra (TN))
2件: Methotrexate,
Tocilizumab (Actemra ACTPen)
2件: Methotrexate ,
Tocilizumab (Actemra (TN)) 💬
3件: DHFR,
DHFR2,
IL6R 💬
17件: Antifolate resistance, Biosynthesis of cofactors, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, Folate biosynthesis, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Metabolic pathways, Non-alcoholic fatty liver disease, One carbon pool by folate, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬1件: 46 💬
186Tocilizumab 162 mg
(Actemra (TN))
1件: Tocilizumab (Actemra ACTPen)1件: Tocilizumab (Actemra (TN)) 💬1件: IL6R 💬12件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬1件: 46 💬
187Tocilizumab 162Mg/0.9Ml Autoinjector
(Actemra (TN))
1件: Tocilizumab (Actemra ACTPen)1件: Tocilizumab (Actemra (TN)) 💬1件: IL6R 💬12件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬1件: 41 💬
188Tocilizumab 162mg/0.9ml jeringa SC
(Actemra (TN))
1件: Tocilizumab (Actemra ACTPen)1件: Tocilizumab (Actemra (TN)) 💬1件: IL6R 💬12件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬1件: 46 💬
189Tocilizumab 162mg/0.9ml SC PFS SC
(Actemra (TN))
1件: Tocilizumab (Actemra ACTPen)1件: Tocilizumab (Actemra (TN)) 💬1件: IL6R 💬12件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬1件: 46 💬
190Tocilizumab 162mg/0.9ml syringe SC
(Actemra (TN))
1件: Tocilizumab (Actemra ACTPen)1件: Tocilizumab (Actemra (TN)) 💬1件: IL6R 💬12件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬1件: 46 💬
191Tocilizumab [RoActemra/Actemra]1件: Tocilizumab (Actemra ACTPen)1件: Tocilizumab (Actemra (TN)) 💬1件: IL6R 💬12件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬4件: 46, 51, 107, 331 💬
192Tocilizumab [RoActemra]
(Actemra (TN))
1件: Tocilizumab (Actemra ACTPen)1件: Tocilizumab (Actemra (TN)) 💬1件: IL6R 💬12件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬1件: 46 💬
193Tocilizumab and IV steroids combination
(Actemra (TN))
1件: Tocilizumab (Actemra ACTPen)1件: Tocilizumab (Actemra (TN)) 💬1件: IL6R 💬12件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬1件: 41 💬
194Tocilizumab Infusion RoAcemtra (EU)
(Actemra (TN))
1件: Tocilizumab (Actemra ACTPen)1件: Tocilizumab (Actemra (TN)) 💬1件: IL6R 💬12件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬1件: 266 💬
195Tocilizumab Injectable Product
(Actemra (TN))
1件: Tocilizumab (Actemra ACTPen)1件: Tocilizumab (Actemra (TN)) 💬1件: IL6R 💬12件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬1件: 11 💬
196Tocilizumab Injection
(Actemra (TN))
1件: Tocilizumab (Actemra ACTPen)1件: Tocilizumab (Actemra (TN)) 💬1件: IL6R 💬12件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬1件: 13 💬
197Tocilizumab Injection 8mg/kg
(Actemra (TN))
1件: Tocilizumab (Actemra ACTPen)1件: Tocilizumab (Actemra (TN)) 💬1件: IL6R 💬12件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬1件: 46 💬
198Tocilizumab IV
(Actemra (TN))
1件: Tocilizumab (Actemra ACTPen)1件: Tocilizumab (Actemra (TN)) 💬1件: IL6R 💬12件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬1件: 46 💬
199Tocilizumab plus methotrexate
(Actemra (TN))
2件: Methotrexate,
Tocilizumab (Actemra ACTPen)
2件: Methotrexate ,
Tocilizumab (Actemra (TN)) 💬
3件: DHFR,
DHFR2,
IL6R 💬
17件: Antifolate resistance, Biosynthesis of cofactors, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, Folate biosynthesis, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Metabolic pathways, Non-alcoholic fatty liver disease, One carbon pool by folate, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬1件: 46 💬
200Tocilizumab Prefilled Syringe
(Actemra (TN))
1件: Tocilizumab (Actemra ACTPen)1件: Tocilizumab (Actemra (TN)) 💬1件: IL6R 💬12件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬2件: 41, 46 💬
201Tocilizumab Roche
(Actemra (TN))
1件: Tocilizumab (Actemra ACTPen)1件: Tocilizumab (Actemra (TN)) 💬1件: IL6R 💬12件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬2件: 46, 107 💬
202TOCILIZUMAB SC
(Actemra (TN))
1件: Tocilizumab (Actemra ACTPen)1件: Tocilizumab (Actemra (TN)) 💬1件: IL6R 💬12件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬3件: 41, 46, 107 💬
203Tocilizumab SC 162 mg/0.9 ml disposable auto-injector (AI)
(Actemra (TN))
1件: Tocilizumab (Actemra ACTPen)1件: Tocilizumab (Actemra (TN)) 💬1件: IL6R 💬12件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬1件: 46 💬
204Tocilizumab SC 162 mg/0.9 ml pre-filled syringe with safety device (PFS)
(Actemra (TN))
1件: Tocilizumab (Actemra ACTPen)1件: Tocilizumab (Actemra (TN)) 💬1件: IL6R 💬12件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬1件: 46 💬
205Tocilizumab SC 162 mg/0.9 ml prefilled syringe with safety device (PFS)
(Actemra (TN))
1件: Tocilizumab (Actemra ACTPen)1件: Tocilizumab (Actemra (TN)) 💬1件: IL6R 💬12件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬1件: 51 💬
206Tocilizumab treatment
(Actemra (TN))
1件: Tocilizumab (Actemra ACTPen)1件: Tocilizumab (Actemra (TN)) 💬1件: IL6R 💬12件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬1件: 41 💬
207Tocilizumab+Methotrexate(MTX)
(Actemra (TN))
2件: Methotrexate,
Tocilizumab (Actemra ACTPen)
2件: Methotrexate ,
Tocilizumab (Actemra (TN)) 💬
3件: DHFR,
DHFR2,
IL6R 💬
17件: Antifolate resistance, Biosynthesis of cofactors, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, Folate biosynthesis, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Metabolic pathways, Non-alcoholic fatty liver disease, One carbon pool by folate, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬1件: 46 💬
208Tocilizumab, Abatacept
(Actemra (TN))
2件: Abatacept,
Tocilizumab (Actemra ACTPen)
2件: Tocilizumab (Actemra (TN)),
Abatacept 💬
3件: CD80,
CD86,
IL6R 💬
25件: Allograft rejection, Autoimmune thyroid disease, Cell adhesion molecules, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, Graft-versus-host disease, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Rheumatoid arthritis, Systemic lupus erythematosus, Th17 cell differentiation, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis, Viral protein interaction with cytokine and cytokine receptor, Virion - Adenovirus 💬1件: 46 💬
209Treatment defined only by active substance----1件: 50 💬
210Tretinoin and Pioglitazone HCL
(Actos (TN))
2件: Pioglitazone (Actoplus Met),
Tretinoin
2件: Tretinoin ,
Pioglitazone (Actos (TN)) 💬
4件: PML,
PPARG,
RARA,
RARB 💬
21件: AMPK signaling pathway, Acute myeloid leukemia, Endocytosis, Estrogen signaling pathway, Gastric cancer, Herpes simplex virus 1 infection, Huntington disease, Influenza A, Lipid and atherosclerosis, Longevity regulating pathway, Non-alcoholic fatty liver disease, Non-small cell lung cancer, Osteoclast differentiation, PPAR signaling pathway, Pathways in cancer, Small cell lung cancer, Th17 cell differentiation, Thermogenesis, Thyroid cancer, Transcriptional misregulation in cancer, Ubiquitin mediated proteolysis 💬1件: 2 💬
211UDCA (Ursodeoxycholic acid)
(Actigall (TN))
1件: Ursodeoxycholic acid (Actigall)1件: Ursodiol (Actigall (TN)) 💬1件: NR1H4 💬1件: Bile secretion 💬1件: 93 💬
212Ursodeoxycholic acid
(Actigall (TN))
1件: Ursodeoxycholic acid (Actigall)1件: Ursodiol (Actigall (TN)) 💬1件: NR1H4 💬1件: Bile secretion 💬10件: 6, 46, 67, 84, 93, 94, 95, 96, 97, 296 💬
213Ursodeoxycholic acid (UDCA)
(Actigall (TN))
1件: Ursodeoxycholic acid (Actigall)1件: Ursodiol (Actigall (TN)) 💬1件: NR1H4 💬1件: Bile secretion 💬1件: 94 💬
214Ursodeoxycholic acid (UDCA) 500 mg
(Actigall (TN))
1件: Ursodeoxycholic acid (Actigall)1件: Ursodiol (Actigall (TN)) 💬1件: NR1H4 💬1件: Bile secretion 💬1件: 46 💬
215Ursodeoxycholic Acid (URSO)
(Actigall (TN))
1件: Ursodeoxycholic acid (Actigall)1件: Ursodiol (Actigall (TN)) 💬1件: NR1H4 💬1件: Bile secretion 💬1件: 93 💬
216Ursodeoxycholic Acid 300mg capsule
(Actigall (TN))
1件: Ursodeoxycholic acid (Actigall)1件: Ursodiol (Actigall (TN)) 💬1件: NR1H4 💬1件: Bile secretion 💬1件: 93 💬
217Ursodeoxycholic Acid 300mg tablet
(Actigall (TN))
1件: Ursodeoxycholic acid (Actigall)1件: Ursodiol (Actigall (TN)) 💬1件: NR1H4 💬1件: Bile secretion 💬1件: 93 💬
218Ursodeoxycholic Acid Capsules
(Actigall (TN))
1件: Ursodeoxycholic acid (Actigall)1件: Ursodiol (Actigall (TN)) 💬1件: NR1H4 💬1件: Bile secretion 💬1件: 93 💬
219Ursodeoxycholic acid combination of immunosuppressive agents
(Actigall (TN))
1件: Ursodeoxycholic acid (Actigall)1件: Ursodiol (Actigall (TN)) 💬1件: NR1H4 💬1件: Bile secretion 💬2件: 93, 95 💬
220Ursodeoxycholic acid combined with total glucosides of paeony
(Actigall (TN))
1件: Ursodeoxycholic acid (Actigall)1件: Ursodiol (Actigall (TN)) 💬1件: NR1H4 💬1件: Bile secretion 💬1件: 93 💬
221Ursodeoxycholic acid only
(Actigall (TN))
1件: Ursodeoxycholic acid (Actigall)1件: Ursodiol (Actigall (TN)) 💬1件: NR1H4 💬1件: Bile secretion 💬1件: 93 💬
222Ursodeoxycholic acid+Low Dose Glucocorticoid(Methylprednisolone)
(Actigall (TN))
2件: Methylprednisolone,
Ursodeoxycholic acid (Actigall)
2件: Methylprednisolone ,
Ursodiol (Actigall (TN)) 💬
2件: NR1H4,
NR3C1 💬
2件: Bile secretion, Neuroactive ligand-receptor interaction 💬1件: 93 💬
223Ursodiol (ursodeoxycholic acid, UDCA)
(Actigall (TN))
1件: Ursodeoxycholic acid (Actigall)1件: Ursodiol (Actigall (TN)) 💬1件: NR1H4 💬1件: Bile secretion 💬1件: 97 💬
224UTTR1147A/RO7021610 (Active)----2件: 96, 97 💬